Decline in cognitive function in Parkinson's disease may be due to dementia with Lewy bodies

doi:10.1136/bmj.316.7136.1022

From trainee to consultant, BMJ Group offers doctors around the world tailored information, special events, learning resources and recruitment services at every step along their career path.

... by doctors, for doctors, for patients
We are open for entries!

Online learning

BMJ Learning

High-quality CME / CPD for doctors and other healthcare professionals. BMJ Learning features hundreds of accredited, peer-reviewed learning modules in text, video, and audio formats. Find out more

Courses and Qualifications

BMJ Masterclasses

BMJ Masterclasses, led by experts, help clinicians to use the latest evidence and recent guidelines in practice and meet their CPD/CME requirements. Find out more

Exam Preparation

The leading provider of online exam preparation, helping over 167,000 healthcare professionals to pass their exams. Find out more

onExamination

Search all BMJ comment articles:

From

Limit by

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Jan Grace, Clinical research associate,
I G McKeith, Professor of old age psychiatry

Department of Old Age Psychiatry, Newcastle General Hospital, Newcastle upon Tyne NE4 6BE
Institute for the Health of the Elderly, University of Newcastle, Newcastle General Hospital, Newcastle upon Tyne NE4 6BE

EDITOR—Donnellan et al report on four patients with Parkinson's disease in whom prescription of oxybutynin was associated with worsening cognitive function.1 Cognitive impairment in Parkinson's disease is common. It has been suggested that when a progressive decline in cognitive function in Parkinson's disease is accompanied by visual hallucinations and fluctuating cognition a secondary diagnosis of dementia with Lewy bodies is made.2 Dementia with …